Literature DB >> 23212762

Regional differences in gallbladder cancer pathogenesis: insights from a comparison of cell cycle-regulatory, PI3K, and pro-angiogenic protein expression.

Jean M Butte1, Javiera Torres, Emanuela F Veras, Kenichi Matsuo, Mithat Gönen, Michael I D'Angelica, Enrique Waugh, Manuel Meneses, Yoshiyaki Inayama, Yuman Fong, Ronald P Dematteo, Hernan De La Fuente, Itaru Endo, David S Klimstra, William R Jarnagin.   

Abstract

BACKGROUND: The variable incidence of gallbladder cancer (GBCA) suggests regional pathogenetic differences. This study compares cell cycle-regulatory, angiogenesis-related, and PI3K pathway protein expression in GBCAs from three continents.
METHODS: Immunohistochemical expression of several proteins was assessed, correlated with clinicopathologic variables, and compared among centers from Chile (Fundación Arturo López Pérez [FALP]), Japan (Yokohama City University [YCU]), and the United States (Memorial Sloan-Kettering Cancer Center [MSKCC]). Hierarchical clustering was used to partition the data based on protein-expression and treatment center.
RESULTS: Tissue from 117 patients (MSKCC = 76; FALP = 22; YCU = 19) was analyzed. Mdm2 overexpression was seen only at MSKCC (p < 0.0001). Absence of p21 (p = 0.03) and VEGFR2 (p = 0.018) were more common and p27 expression was less frequent (p = 0.047) in tumors from YCU. Ki-67 labeling index in YCU tumors (median = 10) was two-thirds lower than at other centers. On hierarchical clustering analysis, all YCU patients (p = 0.017) and those with early tumors (p = 0.017) clustered separately from MSKCC. Median disease-specific survival after curative intent (R0) resection was 27 months and was similar among centers (p = 0.9). Median disease-specific survival of patients with early tumors was 28.4 months and was higher at YCU (not reached, p = 0.06).
CONCLUSIONS: Cell cycle-regulatory protein expression patterns of YCU tumors differed from those treated at FALP and MSKCC. The differential clustering of protein expression and survival in patients with early tumors suggest regional differences in pathogenesis and disease biology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23212762      PMCID: PMC4048130          DOI: 10.1245/s10434-012-2761-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  40 in total

1.  Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries.

Authors:  Jean M Butte; Kenichi Matsuo; Mithat Gönen; Michael I D'Angelica; Enrique Waugh; Peter J Allen; Yuman Fong; Ronald P DeMatteo; Leslie Blumgart; Itaru Endo; Hernán De La Fuente; William R Jarnagin
Journal:  J Am Coll Surg       Date:  2010-11-12       Impact factor: 6.113

2.  An objective assessment of demography of gallbladder cancer.

Authors:  J Ram Kumar; Mallika Tewari; Arundhati Rai; Rohan Sinha; Sadhu C Mohapatra; Hari S Shukla
Journal:  J Surg Oncol       Date:  2006-06-15       Impact factor: 3.454

3.  Expression and clinical significance of the G1-S modulators in intrahepatic cholangiocellular carcinoma.

Authors:  Y Ito; T Takeda; Y Sasaki; M Sakon; T Yamada; S Ishiguro; S Imaoka; M Tsujimoto; N Matsuura
Journal:  Oncology       Date:  2001       Impact factor: 2.935

4.  Patients with gallstones develop gallbladder cancer at an earlier age.

Authors:  U Dutta; B Nagi; P K Garg; S K Sinha; K Singh; R K Tandon
Journal:  Eur J Cancer Prev       Date:  2005-08       Impact factor: 2.497

5.  The prognostic value of p27 in gastric cancer.

Authors:  Jan-Patrik Wiksten; Johan Lundin; Stig Nordling; Arto Kokkola; Kristina von Boguslawski; Caj Haglund
Journal:  Oncology       Date:  2002       Impact factor: 2.935

Review 6.  The cell cycle: a review.

Authors:  K A Schafer
Journal:  Vet Pathol       Date:  1998-11       Impact factor: 2.221

7.  The prognostic value of angiogenesis by Chalkley counting in gallbladder carcinoma.

Authors:  Andréa Oxley da Rocha; Lígia Maria Barbosa Coutinho; Joăo Grigoletti Schall
Journal:  Hepatogastroenterology       Date:  2009 Jan-Feb

Review 8.  PTEN: a new guardian of the genome.

Authors:  Y Yin; W H Shen
Journal:  Oncogene       Date:  2008-09-18       Impact factor: 9.867

9.  Molecular context of the EGFR mutations: evidence for the activation of mTOR/S6K signaling.

Authors:  Esther Conde; Barbara Angulo; Moying Tang; Manuel Morente; Juan Torres-Lanzas; Angel Lopez-Encuentra; Fernando Lopez-Rios; Montserrat Sanchez-Cespedes
Journal:  Clin Cancer Res       Date:  2006-02-01       Impact factor: 12.531

10.  p53 protein overexpression in gallbladder carcinoma and its precursor lesions: an immunohistochemical study.

Authors:  I I Wistuba; A F Gazdar; I Roa; J Albores-Saavedra
Journal:  Hum Pathol       Date:  1996-04       Impact factor: 3.466

View more
  2 in total

1.  Evolution of surgical management of gallbladder carcinoma and impact on outcome: results from two decades at a single-institution.

Authors:  John M Creasy; Debra A Goldman; Mithat Gonen; Vikas Dudeja; Eileen M O'Reilly; Ghassan K Abou-Alfa; Andrea Cercek; James J Harding; Vinod P Balachandran; Jeffrey A Drebin; Peter J Allen; T P Kingham; Michael I D'Angelica; William R Jarnagin
Journal:  HPB (Oxford)       Date:  2019-04-23       Impact factor: 3.647

2.  Inactivation of tumor suppressor gene pten in early and advanced gallbladder cancer.

Authors:  Iván Roa; Gonzalo de Toro; Fernanda Fernández; Anakaren Game; Sergio Muñoz; Xabier de Aretxabala; Milind Javle
Journal:  Diagn Pathol       Date:  2015-08-21       Impact factor: 2.644

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.